Phase I study of a carboplatin-cisplatin-etoposide combination chemotherapy in advanced non-small-cell lung cancer. 1996

H Nakano, and S Tsuchiya, and Y Takei, and K Minato, and S Watanabe, and T Makimoto, and I Naruse, and T Nomoto, and S Ishihara, and A Takise, and K Ezawa, and N Fueki, and H Hoshino, and R Saito, and M Mori
Department of Internal Medicine, National Nishi-Gunma Hospital, Shibukawa, Japan.

Cisplatin (CDDP)-containing chemotherapy has become the mainstay of clinical trials in unresectable non-small-cell lung cancer (NSCLC), but the role of chemotherapy in the routine management of NSCLC remains controversial. We conducted a phase I study with the combination carboplatin (CBDCA), CDDP, and etoposide (Etop) in unresectable NSCLC. CBDCA, at a starting dose of 80 mg/m2, on day 1, was combined with a fixed dose of CDDP (80 mg/m2, day 1) and Etop (80 mg/m2, days 1-3). Escalation was performed after four patients entered at each dose level. If no World Health Organization (WHO) grade 4 toxicity developed after the first cycle in more than half of the patients or WHO grade 3/4 toxicity in more than two thirds, the dose was escalated. The maximum tolerated dose was established at 300 mg/m2 for CBDCA. Thrombocytopenia and leukopenia were the dose-limiting toxicities. No grade 3/4 nonhematologic toxicities were seen. The recommended dose of CBDCA to be combined with CDDP (80 mg/m2, day 1) and Etop (80 mg/m2, days 1-3) is 280 mg/m2. This trial suggests that our combination chemotherapy may be effective in patients with advanced NSCLC. A multicenter phase II study based on these findings is now under way.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

H Nakano, and S Tsuchiya, and Y Takei, and K Minato, and S Watanabe, and T Makimoto, and I Naruse, and T Nomoto, and S Ishihara, and A Takise, and K Ezawa, and N Fueki, and H Hoshino, and R Saito, and M Mori
September 1996, Lung cancer (Amsterdam, Netherlands),
H Nakano, and S Tsuchiya, and Y Takei, and K Minato, and S Watanabe, and T Makimoto, and I Naruse, and T Nomoto, and S Ishihara, and A Takise, and K Ezawa, and N Fueki, and H Hoshino, and R Saito, and M Mori
October 1997, American journal of clinical oncology,
H Nakano, and S Tsuchiya, and Y Takei, and K Minato, and S Watanabe, and T Makimoto, and I Naruse, and T Nomoto, and S Ishihara, and A Takise, and K Ezawa, and N Fueki, and H Hoshino, and R Saito, and M Mori
December 1994, Gan to kagaku ryoho. Cancer & chemotherapy,
H Nakano, and S Tsuchiya, and Y Takei, and K Minato, and S Watanabe, and T Makimoto, and I Naruse, and T Nomoto, and S Ishihara, and A Takise, and K Ezawa, and N Fueki, and H Hoshino, and R Saito, and M Mori
December 1995, The Tokai journal of experimental and clinical medicine,
H Nakano, and S Tsuchiya, and Y Takei, and K Minato, and S Watanabe, and T Makimoto, and I Naruse, and T Nomoto, and S Ishihara, and A Takise, and K Ezawa, and N Fueki, and H Hoshino, and R Saito, and M Mori
February 2000, Annals of oncology : official journal of the European Society for Medical Oncology,
H Nakano, and S Tsuchiya, and Y Takei, and K Minato, and S Watanabe, and T Makimoto, and I Naruse, and T Nomoto, and S Ishihara, and A Takise, and K Ezawa, and N Fueki, and H Hoshino, and R Saito, and M Mori
April 1991, Gan to kagaku ryoho. Cancer & chemotherapy,
H Nakano, and S Tsuchiya, and Y Takei, and K Minato, and S Watanabe, and T Makimoto, and I Naruse, and T Nomoto, and S Ishihara, and A Takise, and K Ezawa, and N Fueki, and H Hoshino, and R Saito, and M Mori
November 1999, British journal of cancer,
H Nakano, and S Tsuchiya, and Y Takei, and K Minato, and S Watanabe, and T Makimoto, and I Naruse, and T Nomoto, and S Ishihara, and A Takise, and K Ezawa, and N Fueki, and H Hoshino, and R Saito, and M Mori
June 2003, Cancer research and treatment,
H Nakano, and S Tsuchiya, and Y Takei, and K Minato, and S Watanabe, and T Makimoto, and I Naruse, and T Nomoto, and S Ishihara, and A Takise, and K Ezawa, and N Fueki, and H Hoshino, and R Saito, and M Mori
June 1988, European journal of cancer & clinical oncology,
H Nakano, and S Tsuchiya, and Y Takei, and K Minato, and S Watanabe, and T Makimoto, and I Naruse, and T Nomoto, and S Ishihara, and A Takise, and K Ezawa, and N Fueki, and H Hoshino, and R Saito, and M Mori
January 1990, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!